Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Cuts Q1 Loss, Prepares to File Ovarian Tumor Test with FDA

NEW YORK (GenomeWeb News) – Vermillion today reported that it had first-quarter revenues of $53,000, compared to $21,000 in the first quarter of 2007, and that it cut its net loss 20 percent year over year.
 
The Fremont, Calif.-based firm is developing molecular diagnostic tests and expects to file its ovarian tumor triage test, called OVA1, with the US Food and Drug Administration within the next couple of months. It also is conducting clinical trials on a test for peripheral arterial disease.
 
Vermillion’s first-quarter product revenues of $5,000 were from sales of thrombotic thrombocytopenic purpura test component materials to the Ohio State University Research Foundation.
 
The firm’s net loss for the quarter was $4.8 million, or $.76 per share, compared to a net loss of $6 million, or $1.54 per share, in the first quarter of 2007.
 
Vermillion’s R&D expenses decreased 5 percent to $1.9 million from $2 million, and its SG&A costs fell 27 percent to $2.7 million from $3.7 million.
 
The company finished the quarter with $8.3 million in cash and cash equivalents.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.